- VIDEO FAQ: Venetoclax in Combination with Standard Intensive AML Induction/Consolidation Therapy with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML - N. Daver, MD (6:03) - Posted 04/22
- VIDEO FAQ: In this setting of the COVID-19 pandemic, will clinical trials continue to enroll patients? - D. Pollyea, MD (1:59) - Posted 04/08
- VIDEO FAQ: What are the advantages and disadvantages of the different FLT3 inhibitors? - A. Perl, MD(1:57) - Posted 04/01
- e-NEWSLETTER: Evolving Treatment Paradigms in AML: New Data and Clinical Trials That Could Change Clinical Practice - N. Daver, MD
- Posted 02/17
- Additional activities...
Top Picks: Accredited Activities
MediCom Worldwide, Inc. would like to recognize and thank the following companies for their educational support of Managing AML.com in 2018-2019
- Agios Pharmaceuticals, Inc.
- Celgene Corporation
- Daiichi Sankyo, Inc.
- Helsinn Healthcare SA
- Jazz Pharmaceuticals
- Pfizer Inc.